(Q54505774)

30 May 2018

title

Increase in the effectiveness of melphalan therapy with progression of MOPC-315 plasmacytoma tumor growth. (English)

1 reference

30 May 2018

1 reference

S Ben-Efraim

1 reference

30 May 2018

R C Bocian

series ordinal

1 reference

30 May 2018

M B Mokyr

series ordinal

1 reference

30 May 2018

S Dray

series ordinal

1 reference

30 May 2018

publication date

1 January 1983

1 reference

30 May 2018

Cancer Immunology, Immunotherapy

published in

1 reference

30 May 2018

volume

1 reference

30 May 2018

issue

1 reference

30 May 2018

page(s)

101-107

1 reference

30 May 2018

Differential tumor immunogenicity of L1210 and its sublines. I. Effect of an increased antigen density on tumor cell surfaces on primary B cell responses in vitro

cites work

1 reference

12 December 2020

Effect of hapten plus antihapten-tumor serum treatment on established rat fibrosarcoma

1 reference

12 December 2020

Analysis of synergy between cyclophosphamide therapy and immunity against a mouse tumour

1 reference

12 December 2020

Collaboration between specific anti-tumor immunity and chemotherapeutic agents

1 reference

12 December 2020

Tumor immunity to murine plasma cell tumors. I. Tumor-associated transplantation antigens of NZB and BALB-c plasma cell tumors

1 reference

12 December 2020

Effect of L-phenylalanine mustard, adriamycin, actinomycin D, and 4'-(9-acridinylamino)methanesulfon-m-anisidide on naturally occurring human spontaneous monocyte-mediated cytotoxicity

1 reference

12 December 2020

[Chemotherapy of multiple myeloma. Review of the recent trials]

1 reference

12 December 2020

Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells

1 reference

12 December 2020

Contribution of host immunity to cyclophosphamide therapy of a chemically-induced murine sarcoma

1 reference

12 December 2020

Potentiation of the cytotoxic action of melphalan and "activated" cyclophosphamide against cultured tumor cells by centrophenoxine

1 reference

12 December 2020

Host immune potentiation of drug responses to a murine mammary adenocarcinoma. II. Effect of melphalan therapy on the host immune system

1 reference

12 December 2020

Therapy of the murine plasmacytoma MOPC 104E: role of the immune response

1 reference

12 December 2020

Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2- lymphocytes

1 reference

12 December 2020

Detection of early and delayed antitumor effects following curative adoptive chemoimmunotherapy of established leukemia

1 reference

12 December 2020

A method for the measurement of L-phenylalanine mustard in the mouse and dog by high-pressure liquid chromatography

1 reference

12 December 2020

Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. I. Enhancement of in vivo rejection responses by combined chemotherapy-immunotherapy.

1 reference

12 December 2020

Adoptive chemoimmunotherapy of cancer in animals: a review of results, principles, and problems

1 reference

12 December 2020

Effectiveness of Murine Leukemia Chemotherapy According to the Immune State: Reconsideration of Correlations Between Chemotherapy, Tumour Cell Killing, and Survival Time

1 reference

12 December 2020

Augmentation of antitumor cytotoxicity of MOPC-315 tumor bearer spleen cells by depletion of dinitrophenol-adherent cells prior to in vitro immunization

1 reference

12 December 2020

Mutagenesis of mouse myeloma cells with 'Melphalan'.

1 reference

12 December 2020

Importance of timing in cyclophosphamide therapy of MOPC-315 tumor-bearing mice

1 reference

12 December 2020

The allogeneic effect on tumor growth. II. Suppression of both ascitic and solid MOPC 315 plasmacytoma by the graft-vs-host reaction, with pathologic correlation

1 reference

12 December 2020

Host immune potentiation of drug responses to a murine mammary adenocarcinoma

1 reference

12 December 2020

Induction of tumor immunity by intratumoral chemotherapy

1 reference

12 December 2020

Differential tumor immunogenicity of DBA/2 mouse lymphoma L1210 and its sublines. II. Increased expression of tumor-associated antigens on subline cells recognized by serologic and transplantation methods

1 reference

12 December 2020

Role of antitumor immunity in cyclophosphamide-induced rejection of subcutaneous nonpalpable MOPC-315 tumors.

1 reference

12 December 2020

Cooperation between cyclophosphamide tumoricidal activity and host antitumor immunity in the cure of mice bearing large MOPC-315 tumors

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF00199699

1 reference

30 May 2018

1 reference

30 May 2018